Chances and risks of SGLT2 inhibitors

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 6, 2012, Pages 551-554

  Mayer, Peter ^a  

^a Federal Institute for Drugs and Medical Devices BfArM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIPIZIDE; GLUCAGON LIKE PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PYELONEPHRITIS; REVIEW; URINARY TRACT INFECTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84862853052     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0720-0     Document Type: Review

References (25)

1. Adeleye O, Faulkner M, Adeola T, ShuTangyie G (2002) Hypernatremia in the elderly. J Natl Med Assoc 94:701-705
2. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206 (Pubitemid 47057766)
3. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334:574-579 (Pubitemid 126537875)
4. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, doubleblind, placebo-controlled trial. Lancet 375:2223-2233
5. Bailey CJ (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32:63-71
6. Basile J (2011) A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. Postgrad Med 123:38-45
7. Chao EC, Henry RR (2010) SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 9:551-559
8. Cryer PE (2008) The barrier of hypoglycemia in diabetes. Diabetes 57:3169-3176
9. Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
10. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343 (Pubitemid 46871135)
11. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagli-flozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, doubleblind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217-2224
12. Groop LC (1992) Sulfonylureas in NIDDM. Diabetes Care 15:737-754
13. Hardman TC, Rutherford P, Dubrey SW, Wierzbicki AS (2010) Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'. Curr Pharm Des 16:3830-3838
14. Ho LT, Kulkarni SS, Lee JC (2011) Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics. Curr Top Med Chem 11:1476-1512
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
16. Jones D (2011) Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 10:645-646
17. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19 (Pubitemid 36237741)
18. Musso G, Gambino R, Cassader M, Pagano G (2011) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. http://informahealthcare.com/doi/abs/10.3109/07853890.2011.560181
19. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015-2022
20. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948 (Pubitemid 37517824)
21. Pfister M, Whaley JM, Zhang L, List JF (2011) Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther 89:621-625
22. Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N, Sasso FC (2011) Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab 12(7):658-666(9)
23. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13:928-938
24. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M (2011) Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol
25. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106-1118